Tempus AI
@tempusai.bsky.social
Tempus is advancing data-driven precision medicine through the practical application of AI in healthcare. It’s About Time. www.tempus.com
Dr. Frederick Wilson + colleagues have identified RASGRF1/2 fusions across a variety of tumor types, gaining insight on incidence, structural diversity, + tissue distribution of this distinct fusion class. 🔗 www.nature.com/articles/s41... @tempusai.bsky.social
Genetic and oncogenic features of RASGRF fusions - npj Precision Oncology
npj Precision Oncology - Genetic and oncogenic features of RASGRF fusions
nature.com
Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing (@tempusai.bsky.social) https://cancerletter.com/drugs-and-targets/20250711_11a/
Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing - The Cancer Letter
Personalis Inc. and Tempus AI Inc. have expanded and extended their strategic collaboration, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are […]
cancerletter.com
"This approach not only increases the likelihood of trial success, but also reduces the financial burden of conducting studies," write Eric Lefkofsky and Norman E. Sharpless cancerletter.com/trials-and-t...
Unlocking the future of precision medicine: The untapped power of RNA - The Cancer Letter
True innovation in healthcare requires us to look beyond the obvious. For years, DNA sequencing has been the key pillar of precision medicine, offering insights into disease predispositions, mechanism...
cancerletter.com
Looking forward to seeing you at #ASCO25! Attend our Industry Expert Theater with Kate Sasser, PhD, Ezra Cohen, MD, and Halla Nimeiri, MD, to discover how we are redefining precision oncology at scale—where our tests fuel smarter decisions and data advances care. Find more info: tempus.co/3S7WDYp
We’re excited to announce a collaboration to develop a companion diagnostic test with Verastem Oncology. Our FDA-approved xT CDx assay is being leveraged as an investigational assay in Verastem’s global Phase 3 RAMP-301 clinical trial. Read more: tempus.co/3H3F9Kw
#NEWS: We are joining forces with @tempusai.bsky.social By combining our experimental data with Tempus AI's real-world data on its AI-powered platform, we aim to pave the way for novel cancer treatments. Learn more: bit.ly/43owlqa #DataScience #Cancer #ResearchCollaboration
At #MIGlobal, Kate Sasser, PhD, our Chief Scientific Officer, participated in the "Accelerating a Healthier Future Through AI" panel." @milkeninstitute.org Watch the full recording here: milkeninstitute.org/content-hub/...
Tempus AI Introduced xH: Its First Whole-Genome Sequencing Test oncodaily.com/insight/temp... #AML #AI #Cancer #MyelodysplasticSyndromes #MDS #Medicine #MyeloproliferativeNeoplasms #OncoDaily #Oncology #Health
Tempus AI Introduced xH: Its First Whole-Genome Sequencing Test - OncoDaily
Tempus AI Introduced xH: Its First Whole-Genome Sequencing Test / Acute Myeloid Leukemia (AML), AI, Andrew Frazier, Brett Mahon, cancer, Derick Hoskinson,
oncodaily.com